Top

Published in:

01-04-2003 | Original Article

Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression

Authors: Agnieszka Masztalerz, Nico Van Rooijen, Willem Den Otter, Linda A. Everse

Published in: Cancer Immunology, Immunotherapy | Issue 4/2003

Abstract

IL-2 and IL-12 are promising anti-tumour agents. However, little attention has been paid to the role of macrophages during IL-2/IL-12 mediated tumour rejection. We studied the role of macrophages during IL-2/IL-12 mediated tumour rejection in DBA/2 mice bearing syngeneic SL2 lymphoma. Local treatment with IL-2 and IL-12 cured 85% of mice with severe metastasised tumour load. In vivo depletion studies showed that macrophages were required for the anti-tumour effect of IL-2 and IL-12. Macrophages could kill tumour cells both non-specifically and by antibody-dependent cellular cytotoxicity (ADCC). Treatment with IL-2, IL-12 or IL-2/IL-12 enhanced production of specific IgG1 immunoglobulins, while treatment with IL-12 and IL-2/IL-12 additionally induced IgG2a production. FcγRII and/or III were essential for ADCC expression after treatment with IL-2 and IL-12. These data show for the first time the essential role of macrophages during IL-2/IL-12 mediated tumour rejection and also suggest that IL-2 and IL-12 act via different mechanisms.

Banchereau J, Briere F, Liu YJ, Rousset F (1994) Molecular control of B lymphocyte growth and differentiation. Stem Cells 12:278PubMed

Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254CrossRefPubMed

Claassen I, Van Rooijen N, Claassen E (1990) A new method for removal of mononuclear phagocytes from heterogenous cell populations 'in vitro', using the liposome-mediated macrophage 'suicide' technique. J Immunol Methods 134:153CrossRefPubMed

De Weger RA, Wilbrink B, Moberts RM, Mans D, Oskam R, Den Otter W (1987) Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice. Cancer Immunol Immunother 24:25PubMed

Dijstelbloem HM, van de Winkel JG, Kallenberg CG (2001) Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22:510CrossRefPubMed

Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L (1995) Interleukin-2 and human monocyte activation. J Leukoc Biol 57:13PubMed

Espinoza-Delgado I, Longo DL, Gusella GL, Varesio L (1990) IL-2 enhances c-fms expression in human monocytes. J Immunol 145:1137PubMed

Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA (1999) The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 162:4472PubMed

Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P (2001) Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 167:221PubMed

10.

Ha SJ, Lee SB, Kim CM, Shin HS, Sung YC (1998) Rapid recruitment of macrophages in interleukin-12-mediated tumour regression. Immunology 95:156PubMed

11.

Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M (2002) Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 35:329CrossRefPubMed

12.

Jackson PG, Evans SR (2000) Intraperitoneal macrophages and tumor immunity: a review. J Surg Oncol 75:146CrossRefPubMed

13.

Kovacs EJ, Brock B, Varesio L, Young HA (1989) IL-2 induction of IL-1 beta mRNA expression in monocytes. Regulation by agents that block second messenger pathways. J Immunol 143:3532PubMed

14.

Maas RA, Dullens HF, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037PubMed

15.

Metzger DW, Buchanan JM, Collins JT, Lester TL, Murray KS, Van Cleave VH (1996) Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci 795:100

16.

Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA (1997) Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol 27:1958PubMed

17.

Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK (1994) Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 152:1047PubMed

18.

Munder M, Mallo M, Eichmann K, Modolell M (1998) Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 187:2103PubMed

19.

Philip R (1988) Cytolysis of tumor necrosis factor (TNF)-resistant tumor targets. Differential cytotoxicity of monocytes activated by the interferons, IL-2, and TNF. J Immunol 140:1345PubMed

20.

Ravetch, JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275PubMed

21.

Ryffel B (1997) Interleukin-12: role of interferon-gamma in IL-12 adverse effects. Clin Immunol Immunopathol 83:18CrossRefPubMed

22.

Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83CrossRefPubMed

23.

Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl LM, Katona IM (1987) Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol 139:1342PubMed

24.

Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH (2001) IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108:51CrossRefPubMed

25.

Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38PubMed

26.

Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination. Ann N Y Acad Sci 795:434PubMed

27.

Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW (1996) Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res 56:1131PubMed

Title: Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression
Authors: Agnieszka Masztalerz
Nico Van Rooijen
Willem Den Otter
Linda A. Everse
Publication date: 01-04-2003
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0381-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2003

Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers

Functional characterization of CTL against gp100 altered peptide ligands

Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells

Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer